NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of antiviral drugs, has registered its Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo ebolavirus and other Ebola viruses in the Democratic Republic of Congo (DRC). The trial is now listed in the Pan African Clinical Trials Registry under identification number PACTR202608748555077, according to a company announcement.
The company previously obtained local regulatory approval from ACOREP to initiate the trial. NanoViricides confirmed that NV-387 has been delivered to the clinical trial site in Ituri province, with first patient dosing expected within one to two weeks, barring any outbreak-related impediments. The adaptive trial design will begin with a single-arm safety and dose run-in phase, followed by a randomized, controlled, open-label efficacy evaluation.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. It is also being evaluated in a separate Phase II clinical trial for Mpox in the DRC. The drug candidate represents a novel approach to antiviral therapy, leveraging NanoViricides' proprietary nanomedicine platform, which uses specially engineered nanomaterials to target and neutralize viruses.
This development is significant because Ebola viruses, including the Bundibugyo strain, continue to pose serious public health threats in Central Africa. The DRC has experienced multiple Ebola outbreaks in recent years, and the availability of an oral treatment like NV-387 could greatly improve patient outcomes and ease the logistical challenges of administering injectable therapies in remote areas.
According to the World Health Organization, Ebola virus disease has a high fatality rate, and current treatments are primarily intravenous monoclonal antibodies, which require cold chain storage and skilled healthcare workers. An oral therapeutic could be administered more easily in community settings, potentially reducing mortality and curbing transmission more effectively.
NanoViricides' platform technology is based on intellectual property licensed from TheraCour Pharma, Inc., and the company holds exclusive sublicensable rights for multiple viral targets, including Ebola and Marburg viruses. The company's lead drug candidate, NV-387, is also being developed for respiratory infections such as RSV, COVID-19, and influenza, as well as other indications.
The registration of this trial is a critical step forward in advancing NV-387 through clinical development. The trial's adaptive design allows for modifications based on interim results, which could accelerate the path to regulatory approval if the drug shows promise. Successful outcomes could have far-reaching implications not only for Ebola but also for other viral diseases lacking effective oral treatments.
Investors and public health officials will be closely monitoring the progress of this trial, as it could signal a major advancement in antiviral therapy. NanoViricides continues to advance its clinical programs, though the company notes that drug development is a lengthy and capital-intensive process, and there is no guarantee of success.
For more information about NanoViricides and its pipeline, visit the company's website at www.nanoviricides.com. The full press release is available at https://nnw.fm/UiQUn.
